Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Magnus Financial Group LLC

Magnus Financial Group LLC increased its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 107.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 53,536 shares of the company's stock after purchasing an additional 27,777 shares during the quarter. Magnus Financial Group LLC owned about 0.09% of Immunome worth $569,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in Immunome by 6.6% during the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after buying an additional 1,520 shares in the last quarter. AQR Capital Management LLC grew its position in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after buying an additional 4,129 shares in the last quarter. Cerity Partners LLC grew its position in Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock worth $776,000 after buying an additional 5,043 shares in the last quarter. Primecap Management Co. CA grew its position in Immunome by 4.5% during the third quarter. Primecap Management Co. CA now owns 280,800 shares of the company's stock worth $4,105,000 after buying an additional 12,000 shares in the last quarter. Finally, FMR LLC grew its position in Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company's stock worth $61,765,000 after buying an additional 13,757 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Clay B. Siegall purchased 66,057 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were bought at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Philip Tsai purchased 21,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the acquisition, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 102,862 shares of company stock worth $978,045. Company insiders own 8.60% of the company's stock.

Immunome Price Performance

IMNM traded up $0.01 during midday trading on Thursday, reaching $10.22. 781,103 shares of the company's stock traded hands, compared to its average volume of 709,257. The firm has a fifty day moving average of $11.31 and a two-hundred day moving average of $12.85. The stock has a market capitalization of $637.93 million, a price-to-earnings ratio of -1.26 and a beta of 1.90. Immunome, Inc. has a 52 week low of $8.97 and a 52 week high of $30.96.

Analyst Upgrades and Downgrades

IMNM has been the subject of several research analyst reports. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They set an "overweight" rating and a $30.00 price target for the company. Piper Sandler dropped their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Finally, Wedbush reissued an "outperform" rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $28.83.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.